Daewoong Pharmaceutical's Diabetes Drug 'Envlo' Shows Blood Sugar Improvement Effects at ADA

Daewoong Pharmaceutical's domestically developed diabetes drug Envlo has been recognized for its efficacy and safety at the world's leading diabetes conference.

Daewoong Pharmaceutical's SGLT-2 inhibitor class diabetes treatment 'Envlo'
[Photo by Daewoong Pharmaceutical]

Daewoong Pharmaceutical announced on the 17th that it will present the integrated analysis results of a Phase 3 clinical trial proving the efficacy and safety of Envlo in patients with mild renal impairment who have difficulty controlling blood sugar at the 84th American Diabetes Association (ADA) conference, held from the 21st to 24th at the Orlando Convention Center in Florida, USA. ADA is the world's largest diabetes and obesity-related conference, gathering more than 15,000 diabetes experts annually.

This study is an integrated analysis of a Phase 3 clinical trial combining Envlo and metformin. It demonstrated superior blood glucose-lowering effects compared to dapagliflozin (original product name Forxiga) in patients with mild renal impairment. Professor Ryu Young-sang of the Department of Endocrinology and Metabolism at Chosun University Hospital is scheduled to present, explaining not only the blood glucose-lowering effects but also benefits such as increased urinary glucose excretion and improved insulin resistance.

The study results confirmed that Envlo significantly reduced glycated hemoglobin (HbA1c) compared to dapagliflozin in patients with mildly decreased renal function. HbA1c is one of the most important indicators in diabetes management as it reflects the average blood glucose control over the past 2 to 3 months. Measuring the change in HbA1c over 24 weeks between Envlo and dapagliflozin, Envlo showed a 0.94% reduction in HbA1c at week 24 in patients with mild renal impairment, while dapagliflozin showed only a 0.77% reduction. The company explained, "Envlo demonstrated 1.2 times stronger blood glucose-lowering effects than dapagliflozin, an existing sodium-glucose co-transporter (SGLT)-2 inhibitor."

In addition, Daewoong Pharmaceutical plans to disclose meaningful effects of Envlo compared to dapagliflozin on fasting blood glucose reduction, increased urinary glucose excretion, and improved insulin resistance through this poster presentation.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “Envlo is gaining attention as a diabetes treatment option that can surpass dapagliflozin,” adding, “The presentation of these research results will serve as an opportunity to showcase the excellence of Envlo, the first SGLT-2 inhibitor developed by a Korean pharmaceutical company, to medical professionals and researchers worldwide.”